Sign in

Gastric and oesophageal cancer: trials that stopped early

Trials on Gastric and oesophageal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

131 stopped trials give a reason in the registry, latest registry update first. 5 more give no reason and are not listed.

  1. Terminated

    A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

    Reason given in the registry

    “Business decision and not related to safety concerns”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Nov 2026.

    Ended
    Jan 2026
    Phase
    Phase 1
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT05462873
  2. Suspended

    Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

    Reason given in the registry

    “End of Initial Phase of Multi-phase protocol”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Nov 2026.

    Phase
    Phase 2/3
    Run by
    National Cancer Institute (NCI)
    Registry record
    NCT03604991
  3. Terminated

    Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

    Reason given in the registry

    “\<75% participation”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Nov 2026.

    Ended
    Nov 2026
    Phase
    Phase 1
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT05075993
  4. Terminated

    Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer

    Reason given in the registry

    “Study closed per SRC Low Accrual Policy.”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Nov 2026.

    Ended
    Jul 2025
    Run by
    University of Washington
    Registry record
    NCT05911243
  5. Suspended

    Adaptive Radiation for Abdominopelvic Metastases

    Reason given in the registry

    “Pending interim analysis”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Nov 2026.

    Phase
    Phase 1
    Run by
    Fox Chase Cancer Center
    Registry record
    NCT05880667
  6. Suspended

    HEARTS Trial for Thoracic Cancers

    Reason given in the registry

    “Funding issues”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Oct 2026.

    Phase
    Phase 2
    Run by
    University of Wisconsin, Madison
    Registry record
    NCT07132918
  7. Suspended

    A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

    Reason given in the registry

    “Protocol is with FDA review, waiting for funding to be released”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 Oct 2026.

    Phase
    Phase 2
    Run by
    Thomas Jefferson University
    Registry record
    NCT04111172
  8. Terminated

    Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

    Reason given in the registry

    “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.”

    Quoted unchanged from ClinicalTrials.gov; record updated 26 Oct 2026.

    Ended
    Oct 2026
    Phase
    Phase 1/2
    Run by
    Merus B.V.
    Registry record
    NCT04868877
  9. Suspended

    Non-endoscopic EC Screening Program in Northern Iran

    Reason given in the registry

    “Waiting to receive capsule sponge device from the manufacturer.”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2026.

    Run by
    Tehran University of Medical Sciences
    Registry record
    NCT02311712
  10. Terminated

    Proton Beam Therapy in the Treatment of Esophageal Cancer

    Reason given in the registry

    “The study is no longer relevant to have open to ensure insurance approval for this patient population”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Oct 2026.

    Ended
    Sept 2026
    Run by
    Washington University School of Medicine
    Registry record
    NCT03482791
  11. Suspended

    RCT of Mobile Apps & FitBit v. Usual Care

    Reason given in the registry

    “Study is paused for interim analysis.”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 Sept 2026.

    Run by
    Weill Medical College of Cornell University
    Registry record
    NCT03623464
  12. Withdrawn

    Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function

    Reason given in the registry

    “Study was withdrawn per sponsor decision after recruitment opened with no participants enrolled.”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 Sept 2026.

    Phase
    Phase 1
    Run by
    Sunshine Lake Pharma Co., Ltd.
    Registry record
    NCT05048368
  13. Terminated

    Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

    Reason given in the registry

    “The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.”

    Quoted unchanged from ClinicalTrials.gov; record updated 22 Sept 2026.

    Ended
    Jan 2026
    Phase
    Phase 1
    Run by
    SystImmune Inc.
    Registry record
    NCT06714617
  14. Withdrawn

    Wet Heparinized Suction for Abdominal Cancer

    Reason given in the registry

    “study no longer proceeding”

    Quoted unchanged from ClinicalTrials.gov; record updated 17 Sept 2026.

    Ended
    Nov 2025
    Run by
    H. Lee Moffitt Cancer Center and Research Institute
    Registry record
    NCT05041335
  15. Terminated

    Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

    Reason given in the registry

    “Trial was rendered as cancelled work ongoing in the book of business.”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Aug 2026.

    Ended
    May 2026
    Phase
    Phase 3
    Run by
    Merck Sharp & Dohme LLC
    Registry record
    NCT04949256
  16. Suspended

    Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer

    Reason given in the registry

    “Gilead's ongoing evaluation of the wider Zimberelimab and Domvanalimab programme, following the outcomes of the STAR-221 study and the discontinuation of EDGE-Gastric studies. No safety concerns have been identified in relation to ZODIAC.”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Aug 2026.

    Phase
    Phase 2
    Run by
    Royal Marsden NHS Foundation Trust
    Registry record
    NCT06250036
  17. Terminated

    Multimodal Al for Precision Diagnosis of Esophageal Cancer

    Reason given in the registry

    “local ethics review”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 Aug 2026.

    Ended
    Jun 2026
    Run by
    Shanghai Zhongshan Hospital
    Registry record
    NCT07629921
  18. Terminated

    18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer

    Reason given in the registry

    “\<75% participation”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Aug 2026.

    Ended
    Aug 2026
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT06549413
  19. Terminated

    A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

    Reason given in the registry

    “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Aug 2026.

    Ended
    Apr 2025
    Phase
    Phase 1/2
    Run by
    NextCure, Inc.
    Registry record
    NCT05572684
  20. Terminated

    A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

    Reason given in the registry

    “The study was closed because the sponsor decided not to continue the development of certain treatment combinations.”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Aug 2026.

    Ended
    Oct 2025
    Phase
    Phase 1/2
    Run by
    Hoffmann-La Roche
    Registry record
    NCT03281369
  21. Terminated

    A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

    Reason given in the registry

    “Sponsor Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Jul 2026.

    Ended
    Nov 2025
    Phase
    Phase 1/2
    Run by
    Amgen
    Registry record
    NCT05322577
  22. Terminated

    NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

    Reason given in the registry

    “The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373 development strategy.”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Jul 2026.

    Ended
    May 2025
    Phase
    Phase 1/2
    Run by
    NuCana plc
    Registry record
    NCT05714553
  23. Terminated

    Oesophagectomy and Chest Wall and Respiratory Function

    Reason given in the registry

    “Study closed before the planned recruitment target was reached because the study period ended before full recruitment could be completed. Recruitment ceased at study closure and data collection was completed for enrolled participants.”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Jul 2026.

    Ended
    Aug 2024
    Run by
    Imperial College London
    Registry record
    NCT03835273
  24. Suspended

    Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

    Reason given in the registry

    “Drugs unavailable”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Jul 2026.

    Phase
    Phase 1
    Run by
    David Wald
    Registry record
    NCT05400122
  25. Withdrawn

    Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer

    Reason given in the registry

    “The sponsor requested to terminate the study.”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Jul 2026.

    Ended
    Apr 2024
    Phase
    Phase 1/2
    Run by
    Chongqing Precision Biotech Co., Ltd
    Registry record
    NCT04348643
  26. Terminated

    Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

    Reason given in the registry

    “Business reasons and not due to any safety concerns”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Jul 2026.

    Ended
    Jul 2025
    Phase
    Phase 1
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT03114319
  27. Terminated

    A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

    Reason given in the registry

    “The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competitive landscape.”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Jul 2026.

    Ended
    Apr 2026
    Phase
    Phase 1
    Run by
    BeOne Medicines
    Registry record
    NCT06585488
  28. Terminated

    A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

    Reason given in the registry

    “Development discontinued.”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 Jun 2026.

    Ended
    May 2026
    Phase
    Phase 1
    Run by
    Day One Biopharmaceuticals, Inc.
    Registry record
    NCT05514717
  29. Terminated

    Assessing Timing of Enteral Feeding Support in Esophageal Cancer Patients on Muscle functTion and Survival

    Reason given in the registry

    “halted prematurely on the occasion of a planned sample size reestimation after 200 randomised patients during which an unexpected futility finding was demonstrated”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Jun 2026.

    Ended
    Dec 2025
    Run by
    University Hospital, Gasthuisberg
    Registry record
    NCT03676478
  30. Terminated

    Study of PF-07265807 in Participants With Metastatic Solid Tumors.

    Reason given in the registry

    “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Jun 2026.

    Ended
    Nov 2024
    Phase
    Phase 1
    Run by
    Pfizer
    Registry record
    NCT04458259

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.